Pancreatic Cancer Research

ResearcherVanderbilt UniversityActive in the last 2 years

Dana Backlund Cardin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0269-9615; OpenAlex author ID A5010469485. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 7, last author 1)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
138
Papers, trials and grants by year

2010: 1 trial · 2011: 1 paper · 2012: 1 trial · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 5 papers · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 27

  1. Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-026-12810-2↗
  2. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  3. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  4. Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registry. Co-author DOI 10.1093/oncolo/oyaf406↗
  5. Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB. Co-author DOI 10.1016/j.esmogo.2024.100049↗
  6. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  7. Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. Co-author DOI 10.3390/cancers14020283↗
  8. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. First author DOI 10.1002/onco.13758↗
  9. Pancreatic Cancer in Young Adults: Can Innovative Approaches Lead to Better Outcomes? Co-author DOI 10.1093/jnci/djab039↗
  10. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Co-author DOI 10.1158/1078-0432.ccr-21-1789↗
  11. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  12. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated … First author DOI 10.1007/s10637-019-00824-1↗
  13. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. First author DOI 10.1007/s11864-020-00763-7↗
  14. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-20-0489↗
  15. Recent advances in the treatment of pancreatic cancer. First author DOI 10.12688/f1000research.21981.1↗
  16. A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. First author DOI 10.1634/theoncologist.2020-0440↗
  17. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. Co-author DOI 10.1016/j.jgo.2018.11.001↗
  18. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  19. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Co-author DOI 10.1007/s10637-017-0519-z↗
  20. Harnessing the Immune System in Pancreatic Cancer. Last author DOI 10.1007/s11864-018-0566-5↗
  21. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000377↗
  22. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomize… Co-author DOI 10.1001/jamaoncol.2016.5383↗
  23. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  24. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  25. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.04.013↗
  26. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Co-author DOI 10.1002/cam4.208↗
  27. Treatment of early-stage pancreatic cancer. First author PMID 21456390↗

Trials 2

  1. Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Principal investigator NCT01660971↗
  2. PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer Principal investigator NCT01227018↗

Closest collaborators

The 25 strongest of 138 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan D. Berlin · 14 shared papers, 2011–2025 · strength 1.74
  2. Vincent M. Chung · 7 shared papers, 2017–2026 · strength 0.79
  3. Cathy Eng · 3 shared papers, 2021–2024 · strength 0.67
  4. Michael Brian LaPelusa · 3 shared papers, 2022–2025 · strength 0.66
  5. Elena Gabriela Chiorean · 6 shared papers, 2017–2026 · strength 0.65
  6. Andrew M. Lowy · 7 shared papers, 2016–2026 · strength 0.59
  7. Efrat Dotan · 6 shared papers, 2017–2021 · strength 0.52
  8. Rajiv Agarwal · 2 shared papers, 2024–2025 · strength 0.51
  9. Christos K Fountzilas · 4 shared papers, 2019–2026 · strength 0.50
  10. Noelle K. LoConte · 5 shared papers, 2016–2026 · strength 0.42
  11. Sushanth Reddy · 2 shared papers, 2026 · strength 0.42
  12. Chan Shen · 2 shared papers, 2022–2024 · strength 0.39
  13. Andrew H. Ko · 4 shared papers, 2017–2026 · strength 0.38
  14. Brian G. Czito · 4 shared papers, 2017–2026 · strength 0.38
  15. Robert A. Wolff · 4 shared papers, 2017–2026 · strength 0.38
  16. Courtney L. Scaife · 4 shared papers, 2017–2026 · strength 0.38
  17. Eric K. Nakakura · 4 shared papers, 2017–2026 · strength 0.38
  18. Mokenge Peter Malafa · 4 shared papers, 2017–2026 · strength 0.38
  19. Jeffrey M. Hardacre · 4 shared papers, 2017–2026 · strength 0.38
  20. Brian Matthew Wolpin · 4 shared papers, 2017–2026 · strength 0.38
  21. Mary E. Dillhoff · 4 shared papers, 2017–2026 · strength 0.38
  22. Al B. Benson · 4 shared papers, 2017–2026 · strength 0.38
  23. Philip A. Philip · 4 shared papers, 2016–2024 · strength 0.38
  24. Satya Das · 2 shared papers, 2018–2020 · strength 0.37
  25. Zev A. Wainberg · 2 shared papers, 2024–2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.